Skip to content

To Evaluate safety and efficacy of hair care product.

To evaluate invivo safety and efficacy of a hair care formulation in terms of reduction in Hair loss - N/AP

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033440
Enrollment
36
Registered
2021-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: hair elixir: Approx. 2 -5 ml of given test product (depending on the length of hair) is to be applied on the whole scalp. Apply the product all over the scalp with the help of fingers

Sponsors

Sahyadri Bio Labs Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Having androgenetic alopecia of class I-2 to I-4 according to Ludwig Scale for females and class II to III (including III, IIIA and IIIvertex) according to Norwood Hamilton Scale for males.

Exclusion criteria

Exclusion criteria: Having naturally fair or white hair Having a dermatosis on the scalp aving history of any harmonal problem. Having surgery history on the scalp (micro transplants �) Refusing the shaving of an area of the scalp of about 1.5 cm², the first day of the study and several times during the study Having presented a factor inducing a telogen effluvium in the 3 months preceding the start of the study (important stress, high fever�) Presenting an acute or chronic general desease or pathology which could have an influence on hair endocrinopathy (diabetes, thyroid�), high blood pressure, renal problems, hepatic problems, known anaemia. Having contact allergy or atopic predisposition. Having history of medical/surgical events that may significantly affect the study outcome eg h/o typhoid or jaundice etc.

Design outcomes

Primary

MeasureTime frame
Reduction in hair loss through assessment of AT ratio (Anagen Vs Telogen Ratio)Timepoint: T0, T14, T26,T28,T42,T54,T56, T70,T82,T84,T102,T118, T120.

Secondary

MeasureTime frame
Assessment of AT ratioTimepoint: T0, T14, T26,T28,T42,T54,T56, T70,T82,T84,T102,T118, T120.

Countries

India

Contacts

Public ContactMr Mohit Lalvani

Mascot Spincontrol India Pvt. Ltd.

raji@mascotspincontrol.in022-43349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026